compound 7c [PMID: 22041175]   Click here for help

GtoPdb Ligand ID: 9931

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 7c [PMID: 22041175] is a novel dual NOX4/NOX1 inhibitor that ameliorates bleomycin-induced pulmonary fibrosis, a finding which suggests that targeting the NOX4/1 activity as a potential molecular mechanism for the treatment of idiopathic pulmonary fibrosis [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 62.51
Molecular weight 420.14
XLogP 4.82
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Clc1ccccc1n1[nH]c2c(c1=O)c1CN(CCCn1c(=O)c2)Cc1ccccc1
Isomeric SMILES Clc1ccccc1n1[nH]c2c(c1=O)c1CN(CCCn1c(=O)c2)Cc1ccccc1
InChI InChI=1S/C23H21ClN4O2/c24-17-9-4-5-10-19(17)28-23(30)22-18(25-28)13-21(29)27-12-6-11-26(15-20(22)27)14-16-7-2-1-3-8-16/h1-5,7-10,13,25H,6,11-12,14-15H2
Immunopharmacology Comments
The NADPH oxidases (NOXs) are involved in the development and progression of inflammation-associated disorders. NOX inhibitors are being investigated as a novel therapeutic modality for the treatment of fibrotic conditions [1] and retinopathy [2] (and cancer [4]). At least some of NOX inhibitors' therapeutic efficacy is associated with anti-inflammatory activity which is mediated by a reduction in ROS levels and modulation of inflammatory mediator expression levels